NO20066077L - Behandlingsmetode for cancer - Google Patents

Behandlingsmetode for cancer

Info

Publication number
NO20066077L
NO20066077L NO20066077A NO20066077A NO20066077L NO 20066077 L NO20066077 L NO 20066077L NO 20066077 A NO20066077 A NO 20066077A NO 20066077 A NO20066077 A NO 20066077A NO 20066077 L NO20066077 L NO 20066077L
Authority
NO
Norway
Prior art keywords
cancer
administering
relates
treating
treatment
Prior art date
Application number
NO20066077A
Other languages
English (en)
Norwegian (no)
Inventor
Mark S Berger
Iman El-Hariry
Tona Morgan Gilmer
Arundathy Nirmalini Pandite
David Rusnak
Neil L Spector
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of NO20066077L publication Critical patent/NO20066077L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20066077A 2004-06-03 2006-12-29 Behandlingsmetode for cancer NO20066077L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57682504P 2004-06-03 2004-06-03
US60679004P 2004-09-02 2004-09-02
PCT/US2005/019053 WO2005120504A2 (en) 2004-06-03 2005-06-01 Cancer treatment method

Publications (1)

Publication Number Publication Date
NO20066077L true NO20066077L (no) 2007-01-31

Family

ID=35503647

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20066077A NO20066077L (no) 2004-06-03 2006-12-29 Behandlingsmetode for cancer

Country Status (14)

Country Link
US (1) US20100063074A1 (pt)
EP (1) EP1768963A4 (pt)
JP (1) JP2008501690A (pt)
KR (1) KR20070030240A (pt)
AU (1) AU2005251722B2 (pt)
BR (1) BRPI0511754A (pt)
CA (1) CA2569132A1 (pt)
IL (1) IL179359A0 (pt)
MA (1) MA28691B1 (pt)
MX (1) MXPA06013635A (pt)
NO (1) NO20066077L (pt)
NZ (1) NZ551622A (pt)
RU (1) RU2006142420A (pt)
WO (1) WO2005120504A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090042994A (ko) * 2006-08-22 2009-05-04 콘서트 파마슈티컬즈, 인크. 4-아미노퀴나졸린 유도체 및 이의 사용방법
WO2009137714A2 (en) 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010017387A2 (en) * 2008-08-06 2010-02-11 Teva Pharmaceutical Industries Ltd. Lapatinib intermediates
EP2158913A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158912A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
ES2673165T3 (es) 2012-03-23 2018-06-20 Array Biopharma, Inc. Dispersión sólida amorfa para la utilización en el tratamiento del cáncer cerebral
EA201992573A1 (ru) 2017-04-28 2020-04-06 Сиэтл Дженетикс, Инк. Лечение her2-положительных злокачественных новообразований

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
TWI307339B (en) * 2000-06-30 2009-03-11 Glaxo Group Ltd Quinazoline ditosylate salt comprounds
EP1353693B1 (en) * 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
JP2004002210A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
JP2004002211A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
MXPA04010166A (es) * 2002-04-16 2005-02-03 Astrazeneca Ab Politerapia para el tratamiento de cancer.
WO2004000094A2 (en) * 2002-06-19 2003-12-31 Smithkline Beecham Corporation Predictive markers in cancer therapy
EP1534674A4 (en) * 2002-08-02 2007-11-28 Immunogen Inc CYTOTOXIC AGENTS CONTAINING NEW, EFFECTIVE TAXANES AND THEIR THERAPEUTIC USE
JP2004144680A (ja) * 2002-10-25 2004-05-20 Nanko Kyo 細胞増殖を制御する物質のスクリーニング方法、及びＳｐ１分子等をヌクレオリン（ｎｕｃｌｅｏｌｉｎ）分子から解離させる物質のスクリーニング方法

Also Published As

Publication number Publication date
NZ551622A (en) 2010-01-29
CA2569132A1 (en) 2005-12-22
RU2006142420A (ru) 2008-07-20
AU2005251722A1 (en) 2005-12-22
AU2005251722B2 (en) 2009-11-12
KR20070030240A (ko) 2007-03-15
BRPI0511754A (pt) 2008-01-02
EP1768963A2 (en) 2007-04-04
MXPA06013635A (es) 2007-02-28
WO2005120504A3 (en) 2006-02-23
IL179359A0 (en) 2007-03-08
JP2008501690A (ja) 2008-01-24
US20100063074A1 (en) 2010-03-11
WO2005120504A2 (en) 2005-12-22
MA28691B1 (fr) 2007-06-01
EP1768963A4 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
NO20072631L (no) Kreftbehandlingsmetode
NO20074366L (no) Fremgangsmate for a behandle gefitmibresistent kreft
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
EA200701302A1 (ru) 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
EA201691142A1 (ru) Ингибиторы мек и способы их применения
DK2068880T3 (da) Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer
NO20062181L (no) Metode for fremstilling av aminokrotonylforbindelser
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
WO2007143483A3 (en) Combination of pazopanib and lapatinib for treating cancer
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
NO20066056L (no) Behandling med Gemcitabin og en EGFR-inhibitor
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
EA200801168A1 (ru) Способ лечения
EA200400674A1 (ru) Соли e-2-метокси-n-(3-(4-(3-метилпиридин-3-илокси)фениламино)хиназолин-6-ил)аллил)ацетамида, их получение и их применение против рака
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
NO20066077L (no) Behandlingsmetode for cancer
ATE541573T1 (de) Pharmazeutische zusammensetzung enthaltend lapatinib
NO20066079L (no) Behandlingsmetode for cancer
WO2008067144A3 (en) Cancer treatment method
NO20066080L (no) Behandling med irinotecan (CPT-11) og en AGFR-inhibitor
WO2006026313A3 (en) Cancer treatment method
ATE472323T1 (de) Behandlung von statin-nebenwirkungen mit uridinderivaten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application